Regarding PEG-IFNα therapy, the immunomodulatory effect of PEG-IFNα can induce a robust qHBsAg decline and the role of qHBsAg in optimizing the management seems quite clear, especially in the context of HBeAg positive infection. The gene discussed is IFNA1; the disease is infection.